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A B S T R A C T
A novel binuclear Cd complex (1) with hydrazone-based ligand was prepared and characterized by spectroscopy
and single crystal X-ray diffraction techniques. Complex 1 reveals a strong pro-apoptotic activity in both human,
mammary adenocarcinoma cells (MCF-7) and pancreatic AsPC-1 cancer stem cells (CSCs). While apoptosis
undergoes mostly caspase-independent, 1 stimulates the activation of intrinsic pathway with noteworthy down
regulation of caspase-8 activity in respect to non-treated controls. Distribution of cells over mitotic division
indicates that 1 caused DNA damage in both cell lines, which is confirmed in DNA interaction studies. Compared
to 1, cisplatin (CDDP) does not achieve cell death in 2D cultured AsPC-1 cells, while induces different pattern of
cell cycle changes and caspase activation in 2D cultured MCF-7 cells, implying that these two compounds do not
share similar mechanism of action. Additionally, 1 acts as a powerful inducer of mitochondrial superoxide
production with dissipated trans-membrane potential in the majority of the treated cells already after 6 h of
incubation. On 3D tumors, 1 displays a superior activity against CSC model, and at 100 μM induces disin-
tegration of spheroids within 2 days of incubation. Fluorescence spectroscopy, along with molecular docking
show that compound 1 binds to the minor groove of DNA. Compound 1 binds to the human serum albumin
(HSA) showing that the HSA can effectively transport and store 1 in the human body. Thus, our current study
strongly supports further investigations on antitumor activity of 1 as a drug candidate for the treatment of highly
resistant pancreatic cancer.
1. Introduction
Cellular malignancy has continually been one of leading cause of
death worldwide. The main relying reason of fatal outcome in malig-
nant patients is the development of multidrug resistance and disease
relapse [1]. Most cancer cells proliferate more rapidly than their normal
counterparts; therefore, most cancer drugs target the cell cycle, either
directly by inhibition of the mitotic spindle, preventing equal division
of DNA to the two daughter cells, or indirectly via DNA damaging [2].
Cisplatin (cis‑[PtCl2(NH3)2]; CDDP) is the first metal-based
chemoterapeutic approved by The Food and Drug Administration
agency in 1978, for which DNA was established as molecular target [3].
Because of its effectiveness in treating a variety of cancers, especially
testicular cancer, for which it has a> 90% cure rate [4], it become a
blockbuster drugs since it remains among the most widely used antic-
ancer chemotherapeutics and component in more active clinical trials
than any other anticancer agent [5]. There were investigations of bio-
logical activity of metal-based compounds before the discovery of an-
ticancer properties of CDDP in 1969 [6]. Nevertheless, its tremendous
success as well as research which started in order to study its
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mechanism of action and improve its side effects by developing new
metal complexes based on platinum and other metals, was the land-
mark and beginning of modern era of Medicinal Inorganic Chemistry
[7]. As a result of such efforts another six CDDP analogues have been
registered as anticancer drugs up to now worldwide [8]. The common
characteristic of all platinum-based approved chemoterapeutics is
covalent binding to DNA, preferably to guanine, resulting in intrastrand
and interstrand DNA cross-links [5,9].
Nowadays almost 50% of reports on biological activity of metal-
containing compounds involve evaluation of their DNA interaction
properties. Although, DNA is generally accepted as a major pharma-
cological target of the majority of metal-based drugs, there are certain
gaps in this paradigm [10]. On the other hand, there are huge number
of evidences that proteins also represent significant cellular targets for
metal complexes [11–14].
A scarcely explored part of medicinal inorganic chemistry is that
related to the potential anticancer activity of Cd complexes, since it has
been classified by the International Agency for Research on Cancer as a
human carcinogen [15]. Cadmium toxicity derives from the fact that it
is rapidly localized intracellularly, mainly in the liver, and then is
bound to metallothionein forming a complex that is slowly transferred
to the bloodstream to be deposited in the kidneys [16]. Some studies
indicate that Cd may exert a paradoxical effect in cancer perhaps de-
pendent on the form it exists in: free Cd, protein-bound Cd, and Cd
complexes. It seems that ligand type used for preparation of Cd com-
plexes may cause their very favorable anti-tumor effects [17]. Ligands
used for preparation of Cd complexes can be classified as: thiosemi-
carbazones [16,18–24], selenosemicarbazones [25–27], hydrazones
[16,27–36], hydrazides [38,39], diimines [40], amides [41,42], amino-
acids [43,44], heterocycles [44–56], macrocycles [58–60], drugs
[61–64], scorpionates [65], natural products [66], thiocarbazates
[67–71] and piperazines [72]. Antiproliferative screening results re-
vealed that in many cases complexation with Cd resulted in better ac-
tivity of obtained complexes in comparison to free ligands [15,20–22,
34–37,39,43–47,59–63,66–68,71] and approved chemotherapeutics
[15,19–22,28,31,36,37,39,40,57,60–63,66–69]. Comparative studies
with Zn(II), Cu(II), Co(II), Ni(II), Ce(IV), Zr(IV), Mn(II), Pb(II), Ca(II),
and Sn(II) metal complexes revealed that Cd(II) complexes possess
better activities [17,21,23,34,36,41,47,49,53,57,61,71]. Mechanistic
studies revealed that Cd(II) complexes kill cancer cells via apoptosis
[25,34,35,38,41,43,54,56,59,71]. Some of the investigated complexes
target DNA non-covalently by groove binding [20], intercalation
[36,38,54,57,60,64] and combined mode of intercalation and groove
binding [45], while in some cases nuclease activity [31,54,57] and
covalent binding similar to CDDP were observed [30]. Also, protea-
somal chymotrypsin-like [34,35,44], proteasomal deubiquitinase [56],
histone deacetylase [43] and telomerase [72] inhibiton properties were
revealed as mode of action of several Cd complexes, as well as inhibi-
tion of incorporation of 3H-thymidine into DNA and the respiration of
tumor cells [18].
In our previous work we investigated biological activity of metal
complexes with hydrazone-based ligands obtained from ethyl hy-
drazinoacetate hydrochloride (haOEt×HCl) and variuous N‑heter-
oaromatic carbonyl compounds [73–79]. Among the investigated
compounds with this type of ligands Zn, Cu and Pd complexes showed
promising anticancer activities [77–79], while Cd compounds have not
been investigated yet. In the current investigation, we prepared a novel
Cd complex by reaction of haOEt×HCl and N‑heteroaromatic carbonyl
compound 2‑acetylpyridine (2‑ap) and tested its anticancer activity on
two distinctive cell lines. Human mammary adenocarcinoma cells
(MCF-7) are well known and widely used model for investigation of
drug activity against breast cancer. Instead of being a cloned cell line
where all cells share identical features, MCF-7 cell culture is a popu-
lation of diverse phenotypes due to different gene expression profile of
cells [80]. Particular characteristic arises from previously defined
ability of breast cancer cells to reproduce phenotypic equilibrium of the
initial tumor bulk when are cultured in vitro conditions [81]. Another
cell line used in this study represents cancer stem cell (CSC) model of
pancreatic adenocarcinoma (AsPC-1), highly resistant to majority of
chemotherapeutic agents used nowadays [82,83] Within a tumor bulk,
CSCs consist scarce subpopulation of immortal cells that are dividing
rapidly unlike stem cells of healthy tissues [84]. CSCs are endowed with
significantly enhanced DNA repairing mechanisms, which together
with their extensive genomic heterogeneity result in creation of mul-
tifarious sub-clones. Each sub-clone has unique epigenomic profile that
enables development of resistant phenotypes to applied anticancer
treatments [85]. Furthermore, CSCs can resort in the dormancy phase,
which is unique strategy to avoid harmful effects of chemotherapeutical
and radiation treatments that target rapidly dividing cells [86,87].
Thus, therapy-induced dormancy is tactical response of CSCs to acquire
epigenetic alterations that are necessary for adaptation to new micro-
environment afterwards they relapse as a more aggressive, drug-re-
sistant phenotype [88]. Treatment that would successfully eliminate
CSCs should either trigger their apoptotic death, or to interfere with
their ability to refuge in dormancy by means of induced differentiation,
therefore increasing their vulnerability to chemo- and radio-therapy.
Up to date, there is no still efficient treatment option against CSCs.
Establishment of new treatment strategy that would efficiently elim-
inate CSCs is set as a crucial need in the cure of malignancy. For those
reasons, our study has been arranged to assess competency of 1 to cause
cell death in CSCs and non-CSCs and estimate its ability to act as
comprehensive anticancer agent that could provide eradication of ma-
lignant disease. Here, we investigated activity of 1 on standardly used
two-dimensional (2D) monolayer cell culture and on three-dimensional
(3D) spheroidal model. The latter, closer to CSCs in a metastatic en-
vironment, is a well-established screening platform known to provide
more reliable readouts on drug activity as compared to classical 2D
framework [89].
2. Experimental
2.1. Chemicals and instrumentation
2-Acetylpyridine (99+%) was obtained from Acros Organics, while
ethyl hydrazinoacetate hydrochloride (97%) and Cd(AcO)2× 2H2O
(p.a.) were obtained from Fluka. All solvents (methanol 99%, diethyl
ether 98.0%) were used without further purification. Elemental ana-
lyses (C, H, N) were performed by the standard micro-methods using an
ELEMENTARVario ELIII C.H.N.S.=O analyzer. IR spectrum was re-
corded on a Thermo Scientific Nicolet 6700 FT-IR spectrophotometer
by the Attenuated Total Reflection (ATR) technique in the region
4000–400 cm−1 (Fig. S1, Supplementary material). Abbreviations used
for IR spectrum: vs, very strong; s, strong; m, medium; w, weak. Molar
conductivity was measured at room temperature (25 °C) on a digital
multimeter CRISON MM41. All NMR spectral measurements were
performed on a Bruker Avance III 500 spectrometer equipped with a
broad-band direct probe. The spectra were recorded at room tempera-
ture in DMSO‑d6. Chemical shifts are given on δ scale relative to tet-
ramethylsilane as internal standard for 1H and 13C or Cd(ClO4)2 in D2O
as external standard for 113Cd. Coupling constants (J) were expressed in
Hz. Abbreviations used for NMR spectra: s, singlet; d, doublet; t, triplet;
br. broad. 1D and 2D spectra are shown in Figs. S2–S11 (Supplementary
material). UV–visible (UV–Vis) spectra were recorded on a GBC Sci-
entific Cintra 6 UV–Vis spectrophotometer (200–1000 nm), using
sample dissolved in DMSO (Fig. S12, Supplementary material).
2.2. Synthesis of [Cd2Cl2(AcO)2(aphaOMe)2] (1)
A solution of haOEt×HCl (0.18 g, 1.16mmol) and 2‑ap (0.14 g,
1.16mmol) in 20mL of MeOH was stirred at 40 °C and then solid Cd
(AcO)2× 2H2O (0.31 g, 1.16mmol) was added in the reaction mixture.
The resulting solution was stirred for 30min at 40 °C. White crystals
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were obtained after slow evaporation of the solvent at the room tem-
perature after three days. The crystals were filtered off and washed with
cold ethanol and diethyl ether. Yield: 0.28 g (58%). Anal. Calcd. for
C24H32Cl2Cd2N6O8 (%): C, 34.80; H, 3.89; N, 10.15. Found: C, 34.66; H,
3.81, N, 10.12. ΛM (2.17×10−3M, H2O)=20.0 Ω−1 cm2mol−1. IR
(ATR, νmax/cm−1): 3263 (m), 1752 (s), 1597 (m), 1541 (vs), 1478 (vs),
1199 (vs), 1016 (m), 642(w), 459 (w). 1H NMR (500.26MHz,
DMSO‑d6) δ: 1.80 (s, 3H), 2.22 (s, 3H), 3.61 (s, 3H), 4.25 (d, 1H,
3J=5.5 Hz), 7.23 (br. t, 1H, 3J=5.5 Hz), 7.42 (t, 1H), 7.84 (d, 1H,
3J=8.5 Hz), 7.91 (br. t, 1H, 3J=8.5 Hz), 8.62 (br. d, 1H). 13C NMR
(126.0MHz, DMSO‑d6) δ: 11.7, 21.8, 51.0, 51.2, 120.9, 123.6, 138.8,
140.7, 148.9, 152.4, 171.6, 177.2. 113Cd NMR (110.95MHz, DMSO‑d6)
δ: 139.3.
2.3. Crystal structure determination
Diffraction data were collected on a Gemini S diffractometer (Oxford
Diffraction), equipped with a Mo Kα radiation source (λ=0.71073 Å)
and a Sapphire CCD detector. Data collection strategy calculation and
data reduction were performed with the CrysAlisPro [90]. Structure was
solved by SHELXT [91], and refined with the SHELXL-2014 [92]. The
SHELXLE [93] was used as a graphical user interface for the refinement
procedures. All non‑hydrogen atoms were refined anisotropically. The
hydrogen atoms attached to C atoms were placed at geometrically
idealized positions with C-H distances fixed to 0.93 and 0.96 Å for sp2
and sp3 C atoms, respectively. Their isotropic displacement parameters
were set equal to 1.2 and 1.5 Ueq of the parent sp2 and sp3 C atoms,
respectively. The hydrogen atoms attached to N atoms were located in
difference Fourier map and refined isotopically. Structures were vali-
dated with PLATON [94] together with extensive use of Mercury CSD
2017 [95] and Cambridge Crystallographic Database (CSD) [96].
A summary of the crystallographic data for crystal structure is given
in Table 1. CCDC 1831819 contains the Supplementary crystallographic
data for this paper. These data can be obtained free of charge from The
Cambridge Crystallographic Data Centre via https://www.ccdc.cam.ac.
uk/structures/.
Calculation of intermolecular interaction energies were performed
by using CE-HF model energies [97] embodied in CrystalExplorer17
[98]. Prior to calculations, the lengths of X–H bonds were normalized to
standard neutron diffraction values. A Hirshfeld surface [99] was cal-
culated for a molecule in the crystal structure, and the number of sur-
face patches was determined to be 18, thus defining the coordination
number of a molecule. Calculations were performed for all 18 mole-
cular pairs comprising of the central molecule and one neighboring
molecule.
2.4. Evaluation of biological activity and computational studies
Detailed protocols for anticancer related experiments (Annexin V
and propidium iodide staining, calculation of ApoC50 concentration,
cell cycle analysis, inhibition of caspase activity, evaluation of caspase-
8 and -9 activities, determination of mitochondrial superoxide gen-
eration, assessment of changes in mitochondrial potential and growth
inhibition of 3D tumor models), DNA binding experiments (agarose gel
electrophoresis and fluorescence measurements), human serum al-
bumin (HSA) interaction experiments, acute lethality assay, as well as
details regarding computational studies can be found in Supplementary
material.
3. Results and discussion
3.1. Synthesis and characterization of 1
In our previous work complexes with ligands based on haOEt×HCl
and N‑heteroaromatic carbonyl compounds were obtained by template
reactions involving corresponding metal salts [73–79,100,101]. It was
found that reactive ethyl-ester group can undergo hydrolysis [100,101]
or trans-esterification reaction and that this processes can be directed
by the solvent used for metal complex preparation [79]. Previously, we
have obtained the Cd(II) complexes with aphaOEt ligand (Scheme 1A),
which represents a condensation product of haOEt×HCl and 2‑ap, by
using EtOH as a solvent [76,100]. In this work a novel Cd(II) complex
with methyl-ester analogue of aphaOEt, i.e. aphaOMe ligand (Scheme
1A), was prepared by template reaction of Cd(AcO)2× 2H2O, 2‑ap and
haOEt×HCl in MeOH (Scheme 1B).
The results of elemental analysis confirmed that aphaOMe ligand
was formed and that there is one chloride, one acetate and one cad-
mium ion per ligand molecule. The existence of acetate anion in 1 was
confirmed by IR spectroscopy. Two very strong bands, characteristic for
bidentate acetate coordination, were observed at 1541 (νas) and 1478
(νs) cm−1 [102]. The molar conductivity of 1 in water is
20.0 Ω−1 cm2mol−1, which is significantly less than threshold value for
1:1 electrolytes [103], confirming that 1 is molecular coordination
compound. The general formula of 1 [Cd2Cl2(AcO)2(aphaOMe)2], is
unequivocally derived from a single crystal X-ray diffraction experi-
ment (vide infra).
3.2. Description of crystal structure
ORTEP drawings of the asymmetric unit and molecular structure of
binuclear complex 1 are depicted in Fig. 1. The complex lies at the
centre of inversion at 1 ½ ½. Each cadmium ion is coordinated with
pyridine and imine nitrogen atoms from in situ obtained aphaOMe li-
gand, two oxygen atoms from acetate ion and two bridging chloride
ions [Cl(1) and its symmetry equivalent at 2− x, 1− y, 1− z]. Due to
deviation of ligands' and acetate ion bite angles from an ideal value of
90°, the geometry around each cadmium ion is distorted octahedral.
The cis bond angles are in the wide range from 54.8 to 116.9°, while the
trans ones vary from 142.0 to 160.1° (Table 2). All coordinative bond
lengths are in the usual range (Table 2). As previously noted for related
Cu(II) and Cd(II) complexes [74,76], the ester oxygen atom from
aphaOMe ligand is not involved in coordination.
3D crystal packing is based on hydrogen bonds and π-π stacking in-
teractions. Each NH group of the ligand is involved in hydrogen bonding
Table 1






a (Å) 8.9762 (5)
b(Å) 13.1627 (7)
c (Å) 13.7226 (8)
β (°) 97.488 (5)
V (Å3) 1607.51 (16)
Z 2
Radiation type Mo Kα
μ (mm−1) 1.54
Crystal size (mm) 0.35× 0.13×0.09
Absorption correction Analytical
Tmin, Tmax 0.671, 0.877
Measured reflections 14,721
Independent reflections 3898
Observed reflections [I > 2σ(I)] 2714
Rint 0.044
(sin θ/λ)max (Å−1) 0.683
R[F2 > 2σ(F2)] 0.048
wR(F2) 0.131
S 1.07
No. of parameters 196
No. of restraints 1
H-atom treatment Mixed
Δρmax, Δρmin (e Å−3) 0.72, −0.93
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with one of the acetate oxygen atoms of another complex molecule
(N3⋯O3i=2.889(7) Å, N3eH3A⋯O3i=149(4)°, i=3/2− x, −½+ y,
½− z) with formation of 2D layers parallel to (1 0 −1) (Fig. 2A). Pyr-
idine fragments are involved in π-π interactions with centroid-centroid
distance of 3.675(4) Å. Stacked rings are almost perfectly align with face-
to-face orientation, as indicated by the corresponding displacement angle
of 13.5° and respective shift of 0.861 Å [104]. The stacking interactions
between neighboring complex molecules expand binuclear units into 1D
supramolecular chains running along [100] direction (Fig. 2B). Within
these chains, two out of four aromatic protons are involved in weak
hydrogen bonds with one of the acetate oxygen atoms and chloride
bridges from neighboring complex units (C4⋯O4i=3.305(8) Å,
C4eH4⋯O4i=158°, i=−1+ x, y, z; C3⋯Cl1ii=3.546(8) Å,
C3eH3⋯Cl1ii=145°, ii=1− x, 1− y, 1− z) (Fig. 2B).
To better understand crystal packing determinants, a qualitative
ranking of intermolecular interactions is necessary, as qualitative rea-
soning on intermolecular cohesion, based only on geometrical para-
meters, can sometimes lead to erroneous conclusions [105]. Therefore,
a calculation of pairwise intermolecular interaction energies by whole-
of-molecule approach, which avoids the focus on specific atom–atom
interactions, was performed. The resulting interaction energies are
summarized in Table S1 (Supplementary material). A general conclu-
sion is that both electrostatic and dispersion terms play equally im-
portant role in total interaction energies. The largest stabilizing energy
(−158 kJmol−1 per pair) is associated with two pairs comprising 1D
supramolecular chains running along [100] direction, while the inter-
action energy between four molecular pairs involved in formation of 2D
Scheme 1. (A) Structures of aphaOEt and aphaOMe ligands. (B) Synthesis of 1.
Fig. 1. Asymmetric unit (A) and perspective view and labelling of the molecular structure of 1 (B). Thermal ellipsoids are at the 40% probability level. Equivalent
atoms are generated by the transformation i=2− x, 1− y, 1− z.
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layers parallel to (1 0 −1) is lower (−100 kJmol−1 per pair). Conse-
quently, interactions between these molecular pairs stand out as
structure determining, since other molecular pairs of the first co-
ordination sphere have significantly lower stabilizing energies
(< 9 kJmol−1, see Table S1, Supplementary material). A topology of
the intermolecular interaction energies for the crystal structure of 1 is
summarized by an energy framework [106], displayed in Fig. 2C and D.
3.3. Solution studies
NMR spectroscopy is very useful technique for determination of
structure of Cd complexes in solution since existence of equilibrium of
free and coordinated organic ligands [107], two mononuclear complex
species [108] or binuclear/mononuclear complex species [109] can be
easily recognized by increased number of signals. 1H, 13C and 113Cd
NMR spectra (Figs. S2–S4, Supplementary material) of 1 recorded in
DMSO‑d6 at ambient temperature exhibit one set of 1H, 13C and 113Cd
resonances. This refers to a single ligand environment, also found in the
solid state structure of 1. Position and number of signals in 1H NMR
spectrum of 1 at ambient temperature remained the same even after
48 h (Fig. S2, Supplementary material). The chemical shift of the 1H,
13C and 15N (derived from 1H-15N HSQC and HMBC spectra) resonances
in 1 are very similar to those found in Cd(II) complex with related
(E)‑ethyl‑2‑(2‑pyridin‑2‑yl‑methylene)hydrazylacetate [75], which in-
dicates that the ligand in 1 is coordinated bidentately via pyridine and
hydrazone nitrogen atoms. A singlet at 1.80 ppm in 1H NMR spectrum
(Fig. S2, Supplementary material) and signals at 21.8 and 177.2 ppm in
13C NMR spectrum of 1 (Fig. S3, Supplementary material) correspond to
an acetate ion. When acetate is coordinated to metal ions particular
deshielding of δ(13C) of the carbonyl carbon is expected [110]. The
downfield shift of the signal of CH3COO in 13C NMR spectrum of 1 in
comparison to the signal of carbonyl carbon atom of uncoordinated
acetate (171.93 ppm) [111] points to the presence of coordinated
acetate. Further evidence for acetate ion coordination is derived from
the NOESY spectrum of 1 wherein correlation signal of methyl group
from acetate ion with methylene protons (CH3COO/C8H2) was observed
due to mutual spatial proximity (Fig. S6, Supplementary material).
Coordination of the ester carbonyl group to Cd(II) in solution can be
excluded, since there is no significant change in the chemical shift of
ester carbonyl carbon atom (C9) in 13C NMR spectrum of 1 in com-
parison to spectra of free ligands similar to aphaOMe [75].
The coordination behavior of Cd(II) is typical of a soft acid and
Table 2















a Symmetry transformations used to generate equiva-
lent atoms: i=2− x, 1− y, 1− z.
Fig. 2. Packing in the crystal structure of 1. Hydrogen atoms, except those involved in hydrogen bonding in (A) and (B), are omitted for clarity. (A) 2D assembly
parallel to (1 0 −1) generated by hydrogen bonding. (B) 1D supramolecular chain along [100] direction formed by π-π stacking interactions of pyridine rings and
weak hydrogen bonds. (C) and (D): Energy frameworks for the total nearest neighbor pairwise interaction energies. The cylinders connect molecular centroids, and
their thickness is proportional to the magnitude of the energy. The numbers indicate energy associated with each cylinder in kJmol−1. Pairwise energies with
magnitudes< 10 kJmol−1 have been omitted for clarity.
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orbital diffuseness of Cd(II) acceptor atom is well matched with diffuse
sulfur donor orbitals [112]. This is corroborated by the strong thiol-
binding ability of Cd(II) [113]. However, sulfoxides which contain O
and S donor atoms, prefer coordination via O atom to Cd(II) [114]. This
is in line with the CSD survey where in all found X-ray structures of Cd
(II) complexes a DMSO molecule was coordinated via O atom ex-
clusively [96]. In presented biological experiments (vide infra) the stock
solution of 1 in DMSO was used as a starting material for testing. To
check if a DMSO molecule is coordinated to Cd(II), 1H NMR spectrum of
freshly prepared solution of 1 in DMSO‑d6 (0.006M), with addition of
5% (vol.) DMSO, was recorded (Fig. S11, Supplementary material).
Generally, S-bound DMSO ligands exhibit 1H NMR chemical shifts ap-
proximately 1 ppm downfield relative to free DMSO (~2.54 ppm),
whereas O-bound DMSO exhibits a smaller downfield shift
(0.05–0.5 ppm) [115]. Since no change in 1H NMR chemical shift of
free DMSO was noticed, even after 24 h (Fig. S11, Supplementary ma-
terial), the coordination of DMSO to Cd(II) ion in solution of 1 can be
excluded.
NMR spectroscopic investigations at ambient temperature revealed
evidence consistent with the presence of just one Cd(II) complex species
in solution of 1. However, existence of one set of signals in NMR spectra
may also correspond to the pentacoordinated mononuclear complex
obtained by the cleavage of the two chloride bridges that give rise to the
dinuclear complex 1. In order to address this issue experimentally ob-
tained UV–Vis spectrum of 1 in DMSO (Fig. S12, Supplementary ma-
terial) was compared to the calculated absorption spectra of free
aphaOMe ligand, pentacoordinated mononuclear complex and di-
nuclear complex 1 (Fig. S13, Supplementary material). Theoretical
spectrum of dinuclear species has strong absorption at 310 nm (H-1→
LUMO) with shoulder band at 265 nm (H-1→ L+2), and shows the
best agreement with the experimental data. As a consequence of change
in the coordination environment, mononuclear Cd complex has addi-
tional transition at 211 nm (Fig. S13, Supplementary material). All
absorptions can be assigned to the intraligand π–π* transitions as it is
indicated by composition of the main molecular orbitals relevant for the
electronic transitions (Fig. S14, Supplementary material).
3.4. Anticancer investigations
3.4.1. Superior pro-apoptotic activity of 1 as compared to CDDP
Pro-apoptotic activity of 1 has been assessed after 24 h incubation
on MCF-7 and AsPC-1 cells by means of Annexin V/PI dual staining
method. Percentages of Annexin V single-stained and double-stained
cells were summarized for each concentration of investigated com-
pound. The computed percentages were charted against corresponding
concentrations and ApoC50 concentration was computed as the one that
corresponds to 50% of whole apoptotic events (early and late apoptosis)
on the concentration-response curve (Fig. S15, Supplementary mate-
rial). Our experimental result reveals a high incidence in apoptotic
death induction and this for both cell lines (Fig. 3, Table 3). Activity of
1 is especially powerful on MCF-7 cells as at 30 μM all cells are Annexin
V/PI positive (Fig. 3). AsPC-1 cells, notorious for broad-spectrum drug
resistance [82,83], are responding surprisingly well to the treatment
with 1 as, at 30 μM more than half of AsPC-1 cells are either in early or
advanced apoptosis. Comparing current with our previously published
data [99,116–118] here investigated complex 1 is the strongest inducer
of apoptosis in AsPC-1 cells, including CDDP. The only metal complex
that induced apoptosis in this CSC model reached significant percentage
of Annexin V-stained cells only at 75 μM [99], as well as the best one
referring to organic compounds [116].
As mentioned before, activity of CDDP on AsPC-1 cells has been
evaluated in our previous work with a very poor outcome [116]. In the
current study, CDDP reveals to be more effective on MCF-7 than AsPC-1
cells, but its pro-apoptotic activity was still less remarkable compared
to 1 (Fig. 3). While more than a half of MCF-7 cells in the samples
subjected to 1 at 10 μM were found as double-stained, CDDP at 75 and
100 μM guided only one third of those cells toward advanced stages of
apoptotic death. Relying on results presented here and those we pre-
viously reported [116–119], 1 showed superior activity on both cell
lines in respect to CDDP or other compounds investigated on CSCs.
3.4.2. Changes in cell cycle distribution indicate on DNA replication issue
The difference in intensity of apoptotic response between MCF-7
and AsPC-1 cells could be originated by either 1 striking different cel-
lular targets in each cell line or by the fact that those cell lines from
different phenotype respond in a differential mode to the same chal-
lenge. Although changes in distribution within mitotic phases cannot
provide more precise information on the mechanism of drug's activity,
those can at least indicate which process within the cell cycle was
mostly distressed by 1. In Fig. 4, noticeable concentration-dependent
shifts in distribution of cells are observed within mitosis when MCF-7
cells are subjected to 1. A slight accumulation in the S phase remains
the dominant alteration in cells treated with 10 μM, progressing to a
mitotic arrest in S phase at 30 μM. Within concentration from 50 to
100 μM, 1 induces G0/G1 blockage with a magnitude increasing in
concentration-dependent manner. Such a rearrangement denotes on
concentration-dependent obstructions during DNA replication.
Seemingly, treating AsPC-1 cells with 1 induces a different kind of
cell cycle rearrangements as for MCF-7 cells (Fig. 4). In the AsPC-1
samples subjected to 1 at 30 μM, cells are hindered to enter the S phase,
thus inducing a mild accumulation in G0/G1. At the higher con-
centrations (50 and 75 μM), cells are found gathered at the S-to-G2
restriction point, whereas treatment at 100 μM results in an arrest in the
S phase. This time changes are accompanied by a concentration-de-
pendent amplification of apoptotic response (Figs. 3 and 4). Cell cycle
alterations seen in samples incubated with 50 and 75 μM indicate that
cells passed the process of chromosomal replication but were restrained
to enter the final phase of mitotic division probably due to necessary
DNA repair. In cells treated with 100 μM, division is delayed during
replication, which suggests that 1 induces at such concentration a da-
mage that had to activate DNA repair mechanisms before accessing S-
to-G2 restriction point.
As stated before, CDDP did not achieve any activity against AsPC-1
cells. Considering its relevance as a reference compound, cell cycle
assessment has been performed and described previously [116]. Here,
CDDP applied in a concentration range from 1 to 50 μM on MCF-7 cells
induces a significant accumulation in G2/M phase (Fig. 4). In none of
those samples the incidence of neither apoptotic nor necrotic events are
notably different compared to non-treated control (Fig. 3). Significant
augmentation in frequency of Annexin V-stained cells is found in the
samples subjected to CDDP at the highest concentrations (75 and
100 μM) with both of them shifting cells to stop in S-to-G2 restriction
point. CDDP is known for its ability to trigger various mechanisms that
affect homeostasis and lead to apoptosis, with liable formation of DNA
lesions [120–124]. Initially, such type of results were reported as ex-
clusively depended on p53 status and drug concentration [125–129].
According to those reports, in cells protected with mutated p53, arrest
at the G2 phase was found as the dominant characteristic, while in-
crease in CDDP concentration induced cell cycle block in the S phase.
On the contrary, in cells with wild-type (wt) p53, arrest in the G1 phase
was found at all concentrations of CDDP. Later on, it was disclosed that
CDDP induces arrest in the S phase in a p53-independent manner [130].
Nevertheless, He et al. [131] recently revealed that such type of cell
cycle arrest strongly depends on pathways activated by particular DNA
damaging agents, including CDDP, rather than on the p53 status of
treated cells. MCF-7 cells used here are reported to have wt p53 status
[132], which is not the case of AsPC-1 cells [133]. Thus, distribution of
cells within mitotic division in MCF-7 samples afterwards treatment
with CDDP (Fig. 4) correspond to previously described data [131]. The
divergence in cell cycle response of MCF-7 cells to 1 and CDDP treat-
ments can be addressed to different types of interference those two
drugs induce during DNA replication. On the other hand, alterations in
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cell cycle distribution of MCF-7 and AsPC-1 cells due to the treatment
with 1 indicate that both cell lines experienced distress during DNA
duplication, while their phenotypic particularities most probably were
accountable for initiation different check points, thus leading to diverse
distribution of cells during mitosis. However, if present results indicate
that 1 induces cell cycle shifts different than for CDDP, thus determi-
nation whether 1 has the ability to establish a strong interaction with
DNA or is involved in a mechanism involved in the regulation of the
DNA replication phase remains to be elucidated.
3.4.3. Compared to CDDP, apoptosis induced by 1 reveals as lower caspase-
dependence with possible interruption in activation of extrinsic pathway
To determine the role of caspases activation in process of apoptotic
death due to 1, impact of Z-VAD-fmk pan-caspase inhibitor on initiation
and evolution of cell death was monitored, as was the activation of
either caspase-8 or -9 after 6 h incubation of 1 at ApoC50 concentration.
As represented in Fig. 5A, apoptotic death shows low caspase-de-
pendency in both cell lines (17 ± 2% and 25 ± 1% for MCF-7 and
AsPC-1 cells, respectively). While co-incubation with Z-VAD-fmk has
almost equivalent consequence on initiation of apoptotic death
(28 ± 7% and 22 ± 3% in MCF-7 and AsPC-1 cells, respectively),
evolution of apoptosis in MCF-7 samples was nearly irrespectively due
to caspases' activity (11 ± 1%) contrary to AsPC-1 cells (32 ± 11%).
According to those data, it is obvious that apoptosis induced by 1 is
partially caspase-dependent in both treated cell lines [134]. Ad-
ditionally, pan-caspase inhibition yielded significant augmentation of
necrotic events (41 ± 8% and 67 ± 2% in MCF-7 and AsPC-1 cells,
respectively), which is an expected consequence of interrupted apop-
totic cascades [38].
Moreover, when treated with 1, both cell lines display strikingly
suppressed activation of caspase-8 (Fig. 5B) and not for caspase-9.
While for MCF-7 percentages of cells with single activated caspase-9 or
both activated caspases were at the level of non-treated controls,
modestly stimulated activation of caspase-9, accompanied by sig-
nificant decrease in cross-talk activation of extrinsic pathway, was the
prominent finding for AsPC-1 cells. Such noticeable decline in active
form of caspase-8, even below basal levels in both cell lines, connotes a
possibility that 1 may directly interfere with the process of caspase-8
activation.
Considering that the cell cycle changes in both cell lines treated with
1 indicate a disturbed DNA replication process (Fig. 4), possible role of
caspase-2 remains to be investigated during further studies [135].
Fig. 3. Incidences of apoptotic and necrotic deaths in cells treated with 1 (A) and CDDP (B) determined after 24 h incubation by means of Annexin V/PI dual staining
method. In Annexin V/PI dot plots cells are discriminated as viable (non-stained cells, lower left quadrant), cells in early phase of apoptosis (Annexin V single-stained
cells, lower right quadrant), cells in advanced phases of cell death of apoptotic death (double-stained cells, upper right quadrant), and necrotic cells (PI single-stained
cells, upper left quadrant). Results are represented as the mean ± SD percentages of two replicates from independent experiments.
Table 3
Computed ApoC50 values for 1 and CDDP according results of Annexin V/PI
double staining method after 24 h incubation.
Compound ApoC50 [μM]
MCF-7 AsPC-1
1 8.3 ± 1.4 20 ± 2
CDDP 85 ± 52 n.d.a
a n.d. - not determined as no activity was observed in the concentration
range 1–100 μM.
Fig. 4. Distribution of cells within phases of mitotic division afterwards 24 h incubation with 1 and CDDP. Results are represented as the mean ± SD percentages of
two replicates from independent experiments.
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Fig. 5. Caspase-dependency of cell death determined over percentages of cell death inhibition after co-incubation with pan-caspase inhibitor with investigated
compounds applied at their ApoC50 concentration (A). Analyses are done after 6 h treatment by means of Annexin V/PI double staining method. Results are expressed
as the mean ± SD of two replicates from independent experiments. Percentages of positive for activated caspase-8, caspase-9 or both caspases determined after 6 h
incubation with investigated compounds applied at their ApoC50 concentrations (B). Results are represented as the mean ± SD of two replicates from two in-
dependent experiments.
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Since CDDP did not induce cell death in AsPC-1 samples, caspase-
dependency of apoptosis triggered with this compound was evaluated
on MCF-7 cells only. Apoptotic death induced by the treatment with
CDDP revealed as more caspase-dependent compared to that caused by
1, with very similar caspase-dependency pattern regarding early and
advanced phases of apoptosis evolution between these two treatments
(Fig. 5A). In MCF-7 samples subjected to CDDP, activation of caspase-8
was the dominant event, accompanied with modestly activated caspase-
9 and cross-talk pathways interaction at the level of non-treated control
(Fig. 5B). This result aditionally demonstrates that 1 and CDDP do not
share analogous mode of action.
3.4.4. Complex 1 is a strong inducer of mitochondrial superoxide
generation
According to previously published research on putative mode of
metal complexes activity [136], cadmium-based small molecules pre-
ferentially interfere with nucleic acid metabolism, membrane function
and induce metabolic stress. As reviewed above, current results on al-
terations in cell cycle distribution indicate that 1 interfered DNA re-
plication process. In addition, it was reported that Cd(II) complexes
have the ability to induce apoptosis through the generation of reactive
oxygen species (ROS) [137]. Although ROS-producing ability is well
known mechanism of Cd(II) toxicity [138,139], this particular feature
cannot be instantly attributed to its complexes with organic ligands.
However, such evidence motivated us to evaluate the potential of 1 to
trigger superoxide (O2%−) production in mitochondrion, knowing this
organelle is the key source of intracellular ROS [140]. The extent of
O2%− accumulation, as the primarily yielded mitochondrial ROS, de-
pends on the balance between rate of O2%− generation and rapidity of
its conversion toward hydrogen peroxide by means of superoxide dis-
mutase (SOD) enzyme. Furthermore, extent of O2%− generation de-
pends on the concentration of the enzyme containing electron carrier,
concentration of electron donor, and the second–rate order constants
for the reaction between them [141]. There are two intracellular iso-
forms of SOD: SOD1 that is located in cytoplasm and intermembrane
mitochondrial space, while SOD2 is situated exclusively within mi-
tochondrion matrix [140]. It was previously demonstrated that both
AsPC-1 and MCF-7 cells have lower expression levels of SOD2 com-
pared to healthy controls [142,143]. Contrary to AsPC-1, MCF-7 cells
additionally have reduced level and activity of mitochondrial SOD1
[143], together with significantly higher extent of uncoupled respira-
tion in respect to normal breast epithelial cells MCF10A [141,144].
Current experiments are run in a way that acknowledges the dif-
ference in susceptibility of those two cell lines to ROS-producing agents
described above. Concentrations of 1 at 50 μM for MCF-7 cells and
75 μM for AsPC-1 cells were chosen considering both are situated on the
top plateau of the corresponding concentration-response curves (Fig.
S15, Supplementary material). ROS-generating properties of CDDP, as a
reference compound, are assessed using the same concentrations, even
on AsPC-1 cells albeit CDDP was previously confirmed as unable to
induce cell death in the 2D CSC model after 24 h of treatment [116].
Incubation with 1 significantly increases the percentage of O2%− pro-
ducing cells in both AsPC-1 and MCF-7 cells (Fig. 6). As expected, the
median quantity of O2%− per cell is greater in MCF-7 samples, with a
2.7-fold increase in median fluorescent intensity (MFI) values, com-
pared to a 1.2-fold of MFI rise in AsPC-1 treated cells. CDDP revealed
lower proficiency in generating O2%− in MCF-7 cells compared to 1,
although it significantly increased size of O2%− positive subpopulation
with gain in MFI values of 1.8-fold than control. Surprisingly, the
average percentage of AsPC-1 cells positive for mitochondrial O2%−
after CDDP treatment remains at the level of non-treated controls, while
the MFI values are even below untreated cells.
ROS originated in mitochondria, rather than from other in-
tracellular sources, are confirmed as one of the most pathogenic factors
when the rate of their production exceeds the homeostatic level
[145,146]. And enhanced mitochondrial ROS production leads to
mitochondrial permeability transition pore (mPTP) opening with con-
sequential dissipation of mitochondrial transmembrane potential (MTP)
and initiation of cell death [140]. Collapse of MTP represents instant
change in permeability of the inner mitochondrial membrane that
permits to molecules of a size up to 1.5 kDa to go through the mem-
brane. The following course of events includes interruption of ATP
synthesis, mitochondrial swelling, and initiation of cell death. In order
to evaluate if enhanced generation of O2%− due to treatments with 1
and CDDP induces mPTP opening, we assessed the MTP status in
treated cells.
In AsPC-1 cells treated with 1, out of 44 ± 3% were positive for
Annexin V and/or 7‑AAD, 36 ± 2% of them were positive for altered
MTP (Fig. 7). Furthermore, among cells with no signs of changed MTP
status, 9.7 ± 0.4% were positive for Annexin V and 5.6 ± 0.8% were
stained with 7‑AAD. Amidst 59 ± 4% of 1-treated MCF-7 cells that
underwent cell death, 54 ± 5% were positive for dissipated MTP,
whereas 5 ± 1% and 5.2 ± 0.1% of those with intact MTP were
stained with Annexin V or 7‑AAD, respectively (Fig. 8). Thus, the re-
markable difference regarding percentages of O2%− generating cells and
MFI values between AsPC-1 and MCF-7 cells (Fig. 6), denotes a dis-
tressed mitochondrial function and integrity (Figs. 7 and 8).
With reference to O2%− production in CDDP-treated AsPC-1 samples
(Fig. 6), it was expected the same treatment would not cause significant
impact on MTP (Fig. 7). However, it could not be predicted that CDDP
acted as MTP stabilizing agent, decreasing incidence of spontaneously
developed alteration of MTP seen in non-treated AsPC-1 cells. Yet the
same phenomenon was found in MCF-7 cells subjected to CDDP (Fig. 8).
While half of MCF-7 cells treated with CDDP were positive for increased
O2%− with almost twice-greater MFI, percentage of cells with dissipated
MTP was also below those of non-treated samples like for AsPC-1. Re-
cently, Marullo et al. [120] showed that mitochondrial ROS generation
is another important mechanism responsible for anticancer activity of
CDDP yet not well characterized previously. In their work, significant
increase in mitochondrial O2%− levels starts after 16 h of CDDP treat-
ment indicating that time course of O2%− production is consistent with
a reduced synthesis of electron transport chain proteins due to forma-
tion of adducts with mitochondrial DNA [147]. Therefore, according to
previously postulated mechanism, increased extent in mitochondrial
O2%− is rather delayed, as a consequence of disrupted protein synthesis,
instead of an early event caused by pro-oxidant activity of CDDP. This is
not in agreement with our observation in MCF-7 cells (Fig. 6). Since in
the current investigation CDDP is employed only as a reference com-
pound, further discussion on possible mechanisms underlying elevated
mitochondrial O2%− formation while preserved MTP (Figs. 6–8), would
be beyond the scope of our study. Final remark concerns the obvious
difference in mechanisms of activity between CDDP and investigated
cadmium complex at the mitochondrial level.
3.4.5. Complex 1 shows a mighty activity on 3D CSC models
Significance and advantages of drug activity testing on 3D models
compared to 2D cultures have been reviewed previously [117,147].
Here, we tested activity of 1 on AsPC-1 and MCF-7 3D cultures over
8 days treatment time, with CDDP as a reference drug. Gained results
provide an excellent illustration of inconsistency between drug's effects
obtained on 2D and 3D models, additionally emphasizing the im-
portance that use of in vitro tumors has for more accurate validation of
preclinical drug development [148,149]. While 1 in 2D MCF-7 model
displayed vigorous pro-apoptotic activity already at 10 μM (Fig. 3), it
achieved growth inhibition of MCF-7 spheroids only at the highest
applied concentration of 100 μM (Figs. 9 and 10). While treatment with
1 at 1 μM did not show any effects, at 10 μM a modest activity with a
2.1 ± 0.1-fold in size increase as compared to 2.5 ± 0.3-fold in non-
treated control on day 8.
For CDDP, examined on MCF-7 3D model previously [150], the
current study confirms its ability to reduce initial size of treated
spheroids at concentrations of 10 μM (0.85 ± 0.04-fold) and 100 μM
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(0.81 ± 0.05-fold). Nevertheless, results on AsPC-1 spheroids disclose
an interesting similarity in pattern of 1 and CDDP activities (Figs. 9 and
11). As reviewed above, CDDP does not induce cell death in AsPC-1 2D
cells over 24 h of incubation [116]. On the contrary, CDDP against
AsPC-1 3D model displays an activity at all 3 tested concentrations
(Figs. 9 and 11). In samples subjected to CDDP at 100 μM, extreme
regression in size is recorded (0.4 ± 0.1-fold on the day 8). CDDP at
10 μM suppresses growth of spheroids (1.0 ± 0.1-fold on the day 8),
while tumors treated with 1 μM record a growth of 1.4 ± 0.1-fold.
Opposite to results on MCF-7 3D model, 1 was more effective on AsPC-1
tumors than CDDP (Figs. 9–11). Complex 1 at 100 μM interrupted
spheroidal assemblage quite promptly after its addition on AsPC-1 3D
tumors (Fig. 11). Initially, such a process produced erroneous im-
pression of gain in size, while after 6 days of treatment spheroids are
completely destroyed. In those samples, residual clustering of cells
could be observed, but those formations were less compact compared to
the one seen after CDDP treatment at the same concentration. The
reason why the disintegration of the spheroidal structure appears so
quickly after 1 was added, as AsPC-1 tumors, may be due to its pro-
apoptotic activity, but the possibility that 1 induces CSCs phenotype
reprogramming with consequential loss of cells' ability to congregate
remains to be further investigated.
3.5. DNA binding studies
As reviewed above, results of the current biological assessment in
both AsPC-1 and MCF-7 cells treated with 1 revealed that the me-
chanism of this compound's activity is most probably related to de-
rangement of DNA replication process. However, the differences in cell
cycle changes at the first place, together with variable pattern in cas-
pases activation and MTP dissipation between 1 and CDDP, strongly
implied that those two compounds do not interrupt cellular homeostasis
Fig. 6. Mitochondrial superoxide (O2%−) generation determined after 6 h treatment with investigated compounds applied at 50 μM (MCF-7 cells) and 75 μM (AsPC-1
cells). Analyses have been performed by means of MitoSox Red staining. Results are represented as percentages of cells positive for O2%− production and over median
fluorescent intensity (MFI) expressed in arbitrary units (AU) computed for O2%−-positive subpopulation. All results are represented as the mean ± SD of two
replicates from 3 independent experiments.
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Fig. 7. Dissipation of mitochondrial transmembrane potential (MTP) in non-treated and treated AsPC-1 cells after 6 h incubation with investigated compounds
applied at 75 μM. In the upper panels cells are discriminated according to the type of cell death (non-stained viable cells and stained with Annexin V and/or 7‑AAD).
In the middle panels cells are discriminated according to staining with MitoSense Red dye (negative cells in lower left and right quadrants have scattered MTP) and
concomitant staining with Annexin V (apoptotic cells in upper right and lower right quadrants). In the lower panels cells are discriminated according to staining with
MitoSense Red dye and concomitant staining with 7‑AAD (cells in necrosis or advanced phase of apoptosis in the upper right or lower right quadrants). All results are
represented as the mean ± SD percentages of two replicates from three independent experiments.
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Fig. 8. Dissipation of mitochondrial transmembrane potential (MTP) in non-treated and treated MCF-7 cells after 6 h incubation with investigated compounds
applied at 50 μM. In the upper panels cells are discriminated according to the type of cell death (non-stained viable cells and stained with Annexin V and/or 7‑AAD).
In the middle panels cells are discriminated according to staining with MitoSense Red dye (negative cells in lower left and right quadrants have scattered MTP) and
concomitant staining with Annexin V (apoptotic cells in upper right and lower right quadrants). In the lower panels cells are discriminated according to staining with
MitoSense Red dye and concomitant staining with 7‑AAD (cells in necrosis or advanced phase of apoptosis in the upper right or lower right quadrants). All results are
represented as the mean ± SD percentages of two replicates from three independent experiments.
S. Bjelogrlić et al. Journal of Inorganic Biochemistry 190 (2019) 45–66
57
in a similar way. According to those facts, it was of interest to further
examine whether direct interaction of 1 with the DNA might be ad-
dressed as the cause for initiation of apoptotic death in both treated cell
lines.
DNA has been generally accepted as a major pharmacological target
of the majority of metal-based drugs [10]. Transition metal complexes
can bind to DNA via both covalent and/or non-covalent interactions. In
general, covalent interactions include coordination to DNA base, sugar
and phosphate moieties, as well as their nuclease activity. In the case of
non-covalent interactions, metal complexes the most frequently interact
with DNA via minor groove, and by intercalation [119]. Detection of
interactions of DNA with potential drugs includes variety of conclusive
electrochemical and spectroscopic methods [151,152]. Among these
methods, simple gel-electrophoresis experiments can give information
about possible covalent interactions with DNA, while fluorescence
spectroscopy competitive experiments are useful to detect non-covalent
interactions and distinguish between intercalative and minor groove
mode of binding [10].
Result of gel electrophoresis experiment could be a retardation of
the migration of plasmid DNA through the gel, which is an indication of
covalent binding [119], or change in the ratio of different forms of DNA
(supercoiled, nicked circular and linear), which further indicates nu-
clease activity of investigated compound [10]. On the other hand, ex-
periments which detect changes in the emission spectra of CT-DNA and
two different dyes EB (a typical DNA intercalator) or H (a minor groove
binder) upon addition of investigated compound are useful to distin-
guish between intercalation and minor groove binding [116]. It is
known that EB emits intense fluorescent light in the presence of DNA
due to its strong intercalation between adjacent base pairs [153]. H
binds strongly and selectively with high affinity to double-stranded B-
DNA structure and, like other minor groove binders, it recognizes at
least four AT base pairs. It binds by combination of hydrogen bonding,
van der Waals contacts with the walls of the minor groove, and
electrostatic interactions between its cationic structure and the DNA
[154]. In both cases the extent of the fluorescence quenching of these
two dyes by competitive displacement from DNA is a measure of the
strength of the interaction between investigated compound and DNA.
3.5.1. Gel electrophoretic study of interaction between 1 and plasmid DNA
The interaction of plasmid pUC19 and 1 was analyzed by agarose
gel electrophoresis (Fig. S16, Supplementary material). In the presence
of the increasing concentration of 1, changes in intensity of fluores-
cence of EB and super-coiled form and open circular form were ob-
served in comparison to the control (lane 1, Fig. S16, Supplementary
material). The increased concentration of 1 produced quenching of
fluorescence of plasmid pUC19 and no changes in band mobility. No
strand scission was observed at concentration up to 0.04mM (lanes
2–5, Fig. S16, Supplementary material). The results show that nuclease
activity and covalent interaction with DNA do not present a mode of
action of 1.
3.5.2. Fluorescence study of interaction between 1 and linear DNA
Since 1 did not emit luminescence upon excitation at π→π* tran-
sitions, both in DMSO or in the presence of CT-DNA, it was possible to
obtain indirect evidence for its binding mode by fluorescent displace-
ment experiments with EB and H dyes. Binding of EB to CT-DNA was
followed by excitation at 500 nm with maximum in fluorescence at
600 nm, while experiments using H dye were followed by excitation at
350 nm with maximum in fluorescence at 444 nm. The emission spectra
of EB bound to CT-DNA in the absence and presence of 1 are given in
Fig. 12A. With increasing concentration of 1 (up to 20 μM), a con-
tinuous decrease in fluorescence intensity at 600 nm for EB–CT-DNA
was observed (Fig. 12A). The complex quenches the fluorescence probe
with the maximal decrease in the fluorescence intensity of the EB–CT-
DNA by 19%, followed by saturation at high concentration of 1 (18 μM)
(Fig. 12A and the inset). However, since the emission intensity of
Fig. 9. Growth rate graphs for MCF-7 and AsPC-1 spheroids, non-treated and treated with investigated compounds. Results are represented as the mean ± SD fold
change of two replicates from independent experiments.
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EB–CT-DNA system upon addition of 1 does not decrease> 50%, which
is generally accepted threshold value if compound interacts with DNA
by intercalation [155], it can be concluded that 1 binds to DNA in a
different mode from EB.
Fig. 12B shows the characteristic emission spectrum of H when it is
bound to CT-DNA. The addition of 1 caused appreciable reduction in
the fluorescence intensity of H–CT-DNA system in a concentration de-
pendent manner. The quenching of H–CT-DNA showed an initial sa-
turation at 10 μM concentration of 1 (inset in Fig. 12B). It is important
to note that the fluorescence intensity was reduced to nearly half of the
initial value at this concentration of 1. The half-reciprocal plot of the
quenching data according to Stern-Volmer (see Supplementary data)
resulted in a linear plot (Fig. 12C) with a quenching constant
Ksv= 3.27. The value is comparable with competition similar values
obtained with other metal complexes binding to minor groove [156].
With increasing concentration of 1, an additional decrease in fluores-
cence intensity was observed, followed by saturation in competitive
displacement from H–CT-DNA system. The decrease of H-CT-DNA
fluorescence intensity was 63% with maximal applied concentration of
1. The obtained results of the extent of the fluorescence quenching of
EB by competitive displacement from EB–CT-DNA system and groove
binder H from H–CT-DNA system demonstrated that 1 is a minor groove
binder.
The DNA interaction study show non-covalent low binding strength
of 1 into DNA minor groove together with the lack of DNA cleavage in
pUC19 experiment. The changes in cell cycle distribution signify that 1
interferes in the process of DNA replication, while comparative analysis
indicates that its mechanism of action differs from the one of CDDP
(vide supra). Taking into account the high affinity of Cd(II) for S ligands,
like thiol groups of enzymes and proteins [113], possible molecular
target of 1 is rather related to protein(s) involved in the control of re-
plication than DNA itself.
3.5.3. Molecular docking of 1 with DNA
Molecular docking showed that the compound 1 preferentially
binds to the minor groove of DNA (Fig. 13). Out of 20 docking solu-
tions, the best 12 positioned compound 1 near or into the minor groove,
and only 3 solutions placed compound 1 in the major groove. Compared
to the HSA binding (vide infra), the ChemPLP docking score for 1-DNA
interaction was significantly smaller (−52.67 compared to −83.50;
Table S2, Supplementary material). This is in line with the experimental
findings that 1 binds with higher affinity to the proteins (HSA, vide
infra) than to DNA.
3.6. Acute lethality assay
As a preliminary toxicity screening, in vivo acute lethality of 1 and
reference compound CDDP were tested on brine shrimp Artemia salina
after 24 h incubation. LC50 value for complex 1 (0.316 ± 0.007mM)
was significantly higher than for CDDP (0.006 ± 0.004mM), which
Fig. 10. Changes in size and morphology of MCF-7 3D spheroids over the 8 days of treatment with investigated compounds. Images have been taken every other day
on Celigo imaging cytometer using Celigo software. Scale bar: 200 μm.
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indicates that CDDP induced higher incidence of lethality in compar-
ison to 1. Since that there is a good correlation between the results of
LC50 obtained in the current bioassay and the results of the Acute Oral
Toxicity Assay in Mice [157], it can be anticipated that 1 would possess
the lower acute toxicity in comparison to CDDP.
3.7. Interaction with HSA
3.7.1. Experimental study of interaction between 1 and HSA
HSA is well known for its binding capacity and repository for an
extraordinarily diverse range of molecules which makes it an important
factor in the pharmacokinetic behavior of many drugs by affecting their
efficiency and rate of delivery. Because of this, the studies of interac-
tions between potential anticancer drugs and HSA as a potential drug
carrier are of great importance in cancer science. Fluorescence spec-
troscopy proved to be useful for characterization of small molecule -
HSA interactions. Aromatic amino acids Tyr, Phe and Trp can emit light
by fluorescence upon excitation with 280 nm light, and among them
Trp has the largest quantum yield. The HSA has only one Trp residue
(Trp214) which is close to two binding sites where the majority of drug
molecules bind (Sudlow site I and II). Upon binding of a small molecule
in the vicinity of Trp214 the microenvironment around this residue
changes, and this reflects on the emission properties of Trp214.
The changes in emission spectra of HSA with the addition of in-
creasing amount of 1 are shown in Fig. 14. As the concentration of 1
increases, results may deviate from initial linearity due to instrumental
inner filter effect [158]. As we used very diluted solutions of HSA and 1,
the absorbances at both excitation and emission wavelength did not
exceed 0.05 even for the most concentrated solution, so inner filter
effect is negligible and therefore raw spectral data were used for further
calculations. The decrease in fluorescence intensity of HSA (fluores-
cence quenching) is observed, with the slight blue shift of maximum
emission at ~340 nm. The change in the maximum emission wave-
length indicates that the microenvironment around Trp214 is altered as
HSA-1 complex is formed. After addition of a maximum amount of
substance, the final volume of DMSO did not exceed 2%. It was shown
that addition of 15% of DMSO does not induce the structural changes in
bovine serum albumin, a protein structurally similar to HSA. Therefore,
it is unlikely that the conformation of HSA will be changed with the
level of DMSO used in this study [159].
Fluorescence quenching data are further processed using Stern-
Volmer (S-V) Eq. (1):
Fig. 11. Changes in size and morphology of AsPC-1 3D spheroids over the 8 days of treatment with investigated compounds. Images have been taken every other day
on Celigo imaging cytometer using Celigo software. Scale bar: 200 μm.
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where F0 and F represents HSA fluorescence intensities in absence (F0)
and in the presence of the quencher (F); Ksv and Kq are S-V's quenching
constant and the quenching rate constant of protein, respectively; τ0 is
the average fluorescence lifetime (7.09 ns for HSA [154]), and [Q] is
the concentration of the quencher (1). The plot F0 / F= f([Q]) is shown
in Fig. S17 (Supplementary material). Up to 4 equivalents of quencher,
S-V's plot is linear with an intercept equal to 1 and slope 5.08×104,
which is the value for binding constant for 1. At higher quencher
concentrations, the plot deviates from linearity as Trp214 residue be-
come less available to the new molecules of the quencher. Once a bulky
molecule of 1 is bound to HSA it makes an approach and binding of a
new quencher molecule more difficult.
To evaluate the fractional accessibility of Trp214 residues, we
analyzed the quenching data using modified S-V Eq. (1) [160]:
= +F







where ΔF is the difference in fluorescence intensity of HSA in the ab-
sence (F0) and in the presence of the quencher at concentration [Q]. Ka
represents the effective quenching constant for the accessible
Fig. 12. (A) Emission spectra (λex 500 nm) of EB (25 μM) bound to CT-DNA
(100 μM, top black line) and quenching of EB–CT-DNA system by 1 at in-
creasing concentrations (0 to 20 μM, curves from top to bottom). The inset
demonstrates the saturation of binding. (B) Emission spectra (λex 350 nm) of H
(28 μM) bound to CT-DNA (100 μM, top black line) and quenching of H–CT-
DNA system by 1 at increasing concentrations (0 to 20 μM, curves from top to
bottom). The inset demonstrates the saturation of binding. (C) Fluorescence
quenching curves of H bound to CT-DNA at λmax 444 nm by 1.
Fig. 13. The most favorable docking solution for 1-DNA interaction.
Fig. 14. Changes in fluorescence emission spectrum of HSA (c=5.0×10−7M,
top black line) upon addition of 1 in the concentration range from 0 to
4.5× 10−6M; t=25 °C, pH=7.35.
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fluorophores, and fa is the fraction of the accessible fluorophore. The
results of linear fit are shown in Fig. S18 (Supplementary material).
Extrapolation to high concentrations of 1 shows that only 25% of total
fluorescence intensity of Trp214 was quenched by 1. As 1 is very bulky
compound, it most probably binds simultaneously in the vicinity of
Trp214 as well as at the surface of HSA, so only a fraction of a total
number of molecules quenches Trp214 emission. Complex 1 binds to
HSA with moderate affinity (Ksv=5.08×104M−1), and the affinity of
1 is high enough to be effectively transported and stored by HSA in the
body.
3.7.2. Molecular docking of 1 with HSA
The docking scores for binding of 1 to three sites of HSA are shown
in Table S2 (Supplementary material). Docking scores are very similar
for all three binding sites. Complex 1 binds to the site IIA with slight
preference. The majority of docking solutions places 1 at the surface of
HSA. The large portion of bound molecule is exposed to the solvent, and
this may explain relatively weak binding constant found for 1. Binding
mode of 1 to the binding site IIA is shown in Fig. 15. The acetate ligand
of 1 interacts with Lys195 and Arg222 through hydrogen bonding (at
distances 2.84 and 3.11 Å, respectively). It also interacts with Ala291
and Glu292 through non-specific, hydrophobic contacts. Complex 1 is
located far from Trp214 (distance is 4.7 Å) and does not interact with
this residue. The fluorescence quenching observed is probably due to
the conformational changes in the surroundings of Trp214, induced by
the binding of 1. The moderate binding constant of 1 to HSA is in line
with the binding mode found through the molecular docking, as there is
a small number of interactions that could stabilize HSA-1 aduct. A large
portion of the bound molecule is solvent-exposed, and water molecules
from the medium can compete for the ligand molecule and destabilize
protein-ligand complex.
4. Conclusion
Current results on biological activity reveal that our novel bi-
nuclear, hydrazone-based cadmium complex 1 is a very strong pro-
apoptotic inducer in both, MCF-7 and AsPC-1 cells, even more powerful
than CDDP, particularly for AsPC-1 CSCs. While changes in cell cycle
distribution signify that 1 interferes in the process of DNA replication,
comparative analysis indicates that its mechanism of action differs from
the one of CDDP. That hypothesis is confirmed in DNA interaction study
where results show non-covalent low binding strength of 1 into DNA
minor groove together with the lack of DNA cleavage in pUC19 ex-
periment, which indicates that its target is rather related to protein(s)
involved in the control of replication than DNA itself. Furthermore,
apoptotic death caused by 1 was maintained mostly in caspase-in-
dependent manner and included activation of intrinsic apoptotic cas-
cade, which was quite the opposite of CDDP. The underlying cause for
suppressed activation of caspase-8, accompanied with significant in-
hibition of cross-talk between intrinsic and extrinsic caspase pathways
in both cell lines treated with 1, remains to be further investigated.
Although 1 has proved to be a powerful inducer of mitochondrial O2%−,
it still remains unclear whether this mechanism could have an im-
portant role in apoptosis induction. Finally, results on 3D spheroids
displayed substantial activity of 1 against CSCs. All these results make 1
as a serious candidate for further investigations on other CSC models
and as a putative treatment of e.g. highly resistant pancreatic cancer.
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